Navigation Links
Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
Date:4/17/2017

SAN DIEGO, April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced three data presentations on etrasimod (APD334) at ASPET 2017 at Experimental Biology (EB).  The conference is taking place April 22-26 at McCormick Place Convention Center in Chicago, IL. 

The presentations encompass preclinical data highlighting the potent and selective immunomodulatory effects of etrasimod in inflammatory bowel disease (IBD), including ulcerative colitis (UC).

The following abstracts will be presented:

Title: Etrasimod, a Novel Sphingosine-1-Phosphate Receptor (S1PR1) Modulator, Lacks Functional Activity at S1P2 Receptors
Day of presentation: Sunday, April 23, 2017
Abstract Number: 6502
Poster Session Title: Cell Signaling and Cancer Therapeutics
Poster Board Number: D148
Location: McCormick Place Convention Center, Hall F

Title:  Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator Inhibits the Development of Colitis in Lymphoid-Null Mice Injected with Colitogenic CD4+ T Cells
Day of presentation: Tuesday, April 25, 2017
Abstract Number: 6337
Poster Session Title: Drug Discovery and Development: Immunomodulation and Inflammation
Poster Board Number: D125
Location: McCormick Place Convention Center, Hall F

Title: Functional Activity of Etrasimod and a Diverse Panel of Sphingosine-1-Phosphate Receptor (S1PR1) Modulators at S1P4 Receptors
Day of presentation: Tuesday, April 25, 2017
Abstract Number: 6545
Poster Session Title: Drug Discovery and Development: Immunomodulation and Inflammation
Poster Board Number: D126
Location: McCormick Place Convention Center, Hall F

About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights.  Our three most advanced investigational clinical programs are ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune indications, and APD371 in Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; Arena's focus, and the potential of its programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-multiple-presentations-at-aspet-2017-at-experimental-biology-300440006.html


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th
2. Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference
3. Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohns and Colitis Organisation - Inflammatory Bowel Diseases 2017
4. Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
5. How These Biotechs Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
6. Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
7. Arena Pharmaceuticals to Host Fourth Quarter and Full Year 2015 Financial Results and Corporate Update Conference Call and Webcast on Monday, February 29
8. Deloitte Corporate Finance LLC Advises The Marena Group, Inc. on its Recapitalization with The Riverside Company
9. Arena Helps Power IoT Revolution
10. Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
11. Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):